[
  {
    "ts": null,
    "headline": "Johnson & Johnson Statement on VENTURA Program",
    "summary": "TITUSVILLE, N.J- Johnson & Johnson has made the decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depressive disorder due to...",
    "url": "https://finnhub.io/api/news?id=0038d3ee60d653c1a5149ca8ea5000fb6b4f7bdb7693144cd264bfe944fbe372",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741344740,
      "headline": "Johnson & Johnson Statement on VENTURA Program",
      "id": 133090650,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "TITUSVILLE, N.J- Johnson & Johnson has made the decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depressive disorder due to...",
      "url": "https://finnhub.io/api/news?id=0038d3ee60d653c1a5149ca8ea5000fb6b4f7bdb7693144cd264bfe944fbe372"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors",
    "summary": "Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising for long-term investors.",
    "url": "https://finnhub.io/api/news?id=a2dd56b014439c476c94b99818c078982b06255bce3559661474d82856504139",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741340054,
      "headline": "Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors",
      "id": 133090283,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398811731/image_1398811731.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising for long-term investors.",
      "url": "https://finnhub.io/api/news?id=a2dd56b014439c476c94b99818c078982b06255bce3559661474d82856504139"
    }
  }
]